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Objectives: Research on pain severity and health outcomes, especially health-
related quality of life (HRQoL), is often done in a specific disease area examining spe-
cific domains within HRQoL. Although important, this research says very little about 
the relationship between general pain severity (across conditions) and domains of 
HRQoL. The purpose of this study was to investigate this relationship using a large 
sample of EU patients diagnosed with pain. MethOds: Data came from the 2013 
EU National Health and Wellness Survey (NHWS; n= 62,000). The NHWS is a cross-
sectional general health survey assessed yearly in the 5 EU (UK, France, Spain, Italy, 
and Germany). Those individuals who reported a diagnosis of one or more pain types 
were the focal subsample of this analysis (n= 14,459). Patients’ HRQoL was assessed 
via the SF-36 and their pain in the past week was measured on an 11 point self-
report scale from 0 “no pain” to 10 “pain as bad as you can imagine”. Results: Initial 
descriptive results showed that there were large mean differences in SF-36 domain 
scores for those with a diagnosis of pain vs. those without. The largest differences 
were observed for the bodily pain (M= 40.91 vs. 51.88, p< .001, d= 1.06), general health 
(M= 42.89 vs. 50.68, p< .001, d= .80), and role emotional (M= 43.93 vs. 51.04, p< .001, 
d= .75) scales. With regard to pain severity in the past week, the strongest correla-
tions were observed for the bodily pain (r= -.63, p< .001) and role physical (r= -.46, 
p< .001) scales. After controlling covariates, these associations still held for both the 
bodily pain (β = -.59, p< .001) and role physical scales (β = -.45, p< .001). The nature of 
the association between severity (e.g., linear, quadratic) was also examined for each 
SF-domain score. cOnclusiOns: Results suggest that the association between 
pain severity and HRQoL is nuanced and that pain affects different domains of 
HRQoL to varying degrees.
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Objectives: Children with GHD can experience physical symptoms and disease-
related impacts on functioning and well-being. However, no GHD-specific measures 
exist to assess these impacts. The purpose of this qualitative study was to collect 
data to support the conceptual validity of a new measure, with a patient-reported 
outcome (PRO) version for older children and an observer-reported outcome 
(ObsRO) version for parents/guardians. MethOds: Focus groups and interviews 
were conducted with 39 children (aged 8–12) with GHD, 31 parents of children with 
GHD (aged 4–12) and eight clinical experts in three countries (Germany, UK, US). 
Interviews were analysed and coded using adapted grounded theory to determine 
overarching themes and concepts. Based on the analysis, a conceptual model of 
the impact of GHD was developed and items for both versions generated and then 
cognitively debriefed. Results: Qualitative analysis found the saturation of con-
cepts was reached with four domains of impact: Symptoms, Physical, Social, and 
Emotional. Sub-concepts included appetite (48%), strength (42%) and energy level 
(38%) for Symptoms; limitations in physical performance (58%) and reaching (44%) 
for Physical; mistaken for younger (58%) and teasing (41%) for Social; and worry 
(55%) and self-confidence (41%) for Emotional. Emotional impacts were often related 
to others’ perception or treatment of the child as younger. Children and parents 
reported consistent symptoms/impacts, although severity of impacts sometimes 
varied. Impacts were moderated by factors including velocity of physical growth 
and age at treatment initiation. All versions were cognitively debriefed in a new 
sample (N= 26: 13 children, 13 parents) and, based on findings, it was determined 
that the PRO version was appropriate for children aged 9–12. A 32-item TRIM-CGHD 
(PRO and ObsRO versions) was finalized. cOnclusiOns: The conceptual validity 
of both versions of the TRIM-CGHD is supported by these qualitative findings and 
the measure is now ready for psychometric validation.
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Objectives: To explore impact of weight loss on patient-reported outcomes in indi-
viduals without type 2 diabetes, but with obesity (BMI ≥ 30 kg/m2) or overweight (BMI 
27.0-29.9 kg/m2) with ≥ one comorbidity. Patients were randomised 2:1 to once-daily 
liraglutide 3.0 mg (n= 2487) or placebo (n= 1244) as adjunct to D&E. MethOds: Impact 
of Weight on Quality of Life–Lite (IWQOL-Lite) and Short-Form 36 v2 (SF-36) question-
naires were administered in countries with validated translations (approx. 82% of 
individuals). Data are reported as estimated change at end-of-trial, derived using 
ANCOVA with LOCF; increased scores signify improvement. This post hoc analysis was 
based on categorical weight change from baseline. Results are reported for liraglutide 
3.0 mg, placebo respectively, as follows: A = weight gain; B = weight loss 0−4.9%; C = 
weight loss 5−9.9%; D = weight loss 10−14.9%; E = weight loss ≥ 15%. Results: For 
individuals in the trial overall, greater proportions treated with liraglutide 3.0 mg 
versus placebo were in the higher weight loss categories: A 7.4%, 34.3%; B 29.5%, 38.6%; 
C 30.1%, 16.6%; D 18.7%, 7.0%; and E 14.4%, 3.5%. For those completing the IWQOL-Lite 
(n= 1890 liraglutide 3.0 mg, n= 886 placebo) and SF-36 (n= 1689, n= 796 respectively), 
similar profiles were observed, with liraglutide 3.0 mg achieving higher categorical 
weight loss than placebo. Changes in IWQOL-Lite total score were lowest in the weight 
Objectives: To cluster health status among adults with hemophilia by applying the 
hidden Markov model (HMM) to account for longitudinal changes in quality of life 
scores and to derive utility weights for each cluster. MethOds: Data were obtained 
from the Hemophilia Utilization Group Studies (HUGS), a prospective, multi-center 
observational study conducted from 2005 to 2013. Demographic and clinical char-
acteristics, bleeding frequency and health-related quality of life (SF-12) at initial 
interview and 3-month follow-up visits for 2 years were collected. This analysis 
included data for 211 adults with hemophilia A or B with at least two observations. 
The HMM was adapted to generate the clusters and to fit the observation sequences, 
which consisted of SF-12 physical component scores (PCS) and mental component 
scores (MCS). Utility weights were derived using Brazier’s algorithm by mapping 
SF-12 scores to a SF-6D scale. Results: Mean age was 34.6 ±13.2 years and 59% had 
severe hemophilia. Data in four unique clusters provided the best fit with the model. 
Mean PCS were [54.2±2.5, 57.1±2.4], [50.4±6.5, 47.3±9.6], [32.4±7.7, 54.4±7.1] and MCS 
were [35.3±7.1, 36.8±8.6] from cluster 1 to cluster 4, respectively. Utility weights 
for each cluster were 0.91±0.05, 0.75±0.11, 0.65±0.11 and 0.55±0.08, respectively. At 
baseline, 49 (23%) adults were classified in cluster 1, 63 (30%) in cluster 2, 67 (32%) in 
cluster 3 and 32 (15%) in cluster 4. Being in a worse health cluster was significantly 
associated with unemployment, low household income, having severe hemophilia 
and higher BMI. The mean bleeding frequencies during a 3-month period were 
1.54±2.62, 3.01±4.91, 3.80±4.09 and 4.83±5.69 among those who were assigned to 
cluster 1 to 4, respectively (p< 0.0001). cOnclusiOns: Health status in hemophilia 
can be described by four mutually exclusive and clinically relevant clusters, which 
provide patients’ value of health outcomes for future economic analyses.
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Objectives: Patients with chronic pain frequently require strong opioids for pain 
relief. While most patients achieve adequate analgesia, a significant minority either 
suffers intolerable side effects and/or inadequate pain relief leading to opioid 
switching. The lack of a National Pain Care Registry does not permit a successful 
investigation in this topic. MethOds: Study population included all outpatients 
with chronic pain voluntarily participating in a cloud based medical surveillance 
system. Each patient was anonymously linked through an alphanumeric code to all 
opioid prescription (Anatomical Therapeutic Chemical code N02A) in a 18-month 
period. Chronic use was defined as taking the medication for more than 90 con-
secutive days. The prevalence of chronic use was calculated as the ratio between 
the number of subjects taking the medications more than 90 days consecutively 
and the total number of subjects with at least one opioid prescription. This study 
aims to assess (a) the pattern of opioid chronic use, (b) switching of active sub-
stance. Results: Out of about 2,400 occasional users of opioids analgesics, 41 (1.7%) 
were chronic users. Women represented 70.7% of chronic users (N= 29). A total of 
37 (90.2%) chronic users switched active substance at least once during the study 
period. cOnclusiOns: In this outpatient population, the majority of chronic users 
switched active substance at least once during the study period. These results may 
suggest that poor pain control or/and unintended side effects could be a leading 
cause of active substance switching. Otherwise, for patients with inadequate pain 
relief and intolerable opioid-related toxicity/adverse effects, a switch to an alterna-
tive opioid may be the only option for symptomatic relief. However, the evidence for 
the effectiveness of opioid switching does not appear to be established.
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Objectives: Hemophilia is a hereditary bleeding disorder characterized by 
spontaneous and traumatic bleeding requiring regular or episodic infusion of 
clotting factor. Taking care of a child with hemophilia (CWH) is burdensome for 
caregivers. For the assessment of caregivers’ burden standardized question-
naires are needed. We developed the “Hemophilia associated Caregiver Burden 
Scale” (HEMOCABTM). MethOds: Questionnaire development included: 1) item 
generation (two semi-structured focus groups with 11 caregivers, evaluation of 
existing caregiver burden scales for relevance by 16 HCPs); 2) feasibility test-
ing (cognitive interviews with 12 caregivers) and 3) pilot-testing in caregivers 
of CWH with and without inhibitors < 22 years old (psychometric analysis of 
HEMOCABTM). Results: Item generation resulted in a revised questionnaire 
containing 108 questions pertaining to 13 domains. Forty caregivers (75% moth-
ers) completed the HEMOCABTM (mean age of 39.32±8.9). The majority of CWH 
had hemophilia A (95%), inhibitors (15%), were severely affected by hemophilia 
(77.5%), and had 4.83±8.9 bleeds in the last year. Caregivers reported spending 
8.69±7.7 hours per month on infusion and 3.84±6.7 hours per month travelling to 
the hemophilia centre. Psychometric testing of the HEMOCABTM showed good 
values for reliability (Cronbach’s alpha of TOTAL score: α = .97; ‘FREQUENCY’: α = .95 
and ‘BURDEN’: α = .92) and validity (convergent, known groups). HEMOCABTM 
correlated highly with the IOF (r= -.867 for total score) and revealed signifi-
cant differences among caregivers of CWH with inhibitors vs. without in all 
domains of HEMOCABTM except for ‘school’. Caregivers reported highest bur-
den in the domains ‘perception of child’, ‘emotional stress’ and ‘financial bur-
den’. cOnclusiOns: Based on item and scale analysis 49 items were deleted and 
the final HEMOCABTM consists of 59 items. HEMOCABTM is the first hemophilia-
specific instrument for the assessment of caregiver burden with good psychomet-
ric characteristics in terms of reliability and validity. In a next step we will examine 
the sensitivity to change of the revised HEMOCABTM.
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while controlling for length of diagnosis, sociodemographics, and general health char-
acteristics. Results: A total of 346 respondents were included in the analysis; mean 
age was 55 years, 55% were male, and 55% were employed. Pain severity was 3/10 
for the 1st quartile, 5/10 for the median, and 7/10 for the 3rd quartile of this sample. 
Increasing severity was associated with lower scores for mental (MCS) and physi-
cal component summaries (PCS) and SF-6D health utility, higher depression (PHQ-9) 
and anxiety (GAD-7) scores, greater absenteeism and presenteeism, greater activity 
impairment, more healthcare provider visits, and more emergency visits (all p< 0.05). 
As pain severity increased from the 1st to 3rdquartile, MCS, PCS, and SF-6D all declined 
more than the minimally important difference, while work and activity impairments 
approximately doubled. cOnclusiOns: The impact of CLBP on HRQoL, depression 
and anxiety symptoms, impairment to work and daily activities, and healthcare 
use increases with the severity of pain. Interventions reducing severity of pain may 
improve numerous health outcomes even if the pain cannot be eliminated.
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PAtientS with moderAte to Severe PSoriASiS
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Objectives: Psoriasis is prevalent in approximately 3% of the population, and often 
results in significant quality of life losses. The aim of this study was to investigate 
the relationship between disease severity and quality of life (QOL) measured by the 
psoriasis area severity index (PASI) and EQ-5D, respectively. MethOds: Longitudinal 
data from a population-based registry in Sweden (PsoReg) were analysed. PsoReg 
includes patients with moderate to severe psoriasis receiving systemic treatment 
from a specialist with data available from 2006 to 2014. The analysis was conducted 
using all complete observations for adult patients at each healthcare contact date. A 
fixed effects (FE) model was estimated, where time-invariant patient-specific effects 
were modelled. Time-invariance refers to variables that do not change over time, 
such as sex or personality. PASI, PASI squared, age, body mass index, smoking status, 
and presence of psoriatic arthritis were included in the regression as independent 
variables. PASI squared accounts for a nonlinear relationship between PASI and 
EQ-5D. The model was tested for the appropriateness of random effects and exist-
ence of group-wise homoscedasticity, both of which were rejected at an alpha level 
of 0.01. Therefore the final model used FE and robust standard errors. Results: The 
estimation utilised 15,099 observations in 3,838 groups, resulting in an average of 3.9 
observations per patient. The results indicate that each unit increase in PASI is cor-
related with a reduction in EQ-5D, but at a decreasing rate: the estimates of PASI and 
PASI squared were -0.0178 (p< 0.001) and 0.0002 (p< 0.001) respectively. This implies 
that an increase in PASI of 10 (20) units results in a decrease in EQ-5D of 0.1571 
(0.2717) holding other variables constant at their respective means. The (adjusted) 
R2 was (0.5279) 0.6481. cOnclusiOns: QOL in psoriasis patients is decreasing as 
disease severity increases, but at a decreasing rate.
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Objectives: Total hip and knee arthroplasty operations are commonly performed 
to improve patients’ quality of life. The aim of this study is evaluation of patients’ 
quality of life of preoperation and early postoperation after total hip and knee 
arthroplasty. MethOds: This study included 26 patients undergoing total hip and 
knee arthroplasty. After the literature review, 15-items questionnaire was prepared 
for collecting data related to sociodemographic, medical and functional status 
information, including age, sex, previous hip and knee arthroplasty and pain level. 
Quality of life were measured by using the EQ-5D and Visual Analog Scale (VAS). 
During the study, questionarries were administered to patients 2 times: one week 
prior to operation and 45 days following operation. Results: The average age of 
participants was 67,12 years (SD: 10,527). Participants were composed of 80,8% 
females and 19,2% males. Small improvements were reported for pain and func-
tional status after the operations, while large changes were seen in the patients’ 
quality of life. The EQ-5D scores improved significantly preoperatively to postop-
ertively (p< 0,05) (0,322 vs 0,844). Similarly, there was a significant improvement in 
VAS scores preoperatively to postoperatively (p< 0,05) (4,72 vs 7,78). cOnclusiOns: 
Total hip and knee arthroplasties are well accepted as reliable and suitable surgical 
procedures to return patients to function and improve the quality of life of patients’.
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Objectives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. The 
purpose of this study was to assess the health-related quality of life (HRQoL) fac-
tors for TTR-FAP patients. MethOds: HRQoL was measured using the validated 
EuroQoL five dimensions three levels (EQ-5D-3L) questionnaire being the index 
score calculated trough the Portuguese scoring algorithm. TTR-FAP symptomatic 
patients specific data (n = 566) extracted from Transthyretin Amyloidosis Outcomes 
Survey (THAOS) registry. Demographic variables include gender and age. Clinical 
variables include disease onset (early/late), polyneuropathy disability (PND) score, 
liver transplant and pharmacologic treatment. Econometric analyses were car-
ried out to identify factors that impact TTR-FAP HRQoL. Results: In a scale from 
-0.50 to 1.00 the average utility score 0.50(0.37) for symptomatic TTR-FAP patients. 
Within TTR-FAP population, significant statistical effect (p-value < 0.005) was 
gain category (3.45, 3.97) and increased with increasing categorical weight loss: B 7.63, 
7.61; C 10.61, 10.92; D 12.61, 16.50; E 17.27, 15.35. Changes in SF-36 physical component 
summary scores, but not mental component summary scores, followed a similar pat-
tern. cOnclusiOns: We observed higher proportions of subjects achieving greater 
categorical weight loss with liraglutide 3.0 mg versus placebo as adjunct to D&E. With 
greater categorical weight loss, greater improvements in IWQOL-Lite total and SF-36 
physical component summary scores were observed.
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Objectives: Sickle-cell disease (SCD) manifests clinically as severe pain episodes 
in various locations of the body. Patients with SCD also experience chronic daily 
pain, which profoundly affects quality of life. Cognitive interviews were conducted 
to evaluate comprehension and usability of a modified version of the Faces Pain 
Scale-Revised (Modified FPS-R), which asks children to rate their worst pain today 
using an electronic device. MethOds: In-person interviews were conducted in the 
US with children aged 4-17 years with SCD and their parent/legal guardian. Children 
who were unable to read or needed guidance were assisted by their parent/legal 
guardian using written administration guidelines. Children were asked questions 
about their pain experience, understanding of the instrument, and ability to use 
the electronic device. Parents/legal guardians were debriefed on the administra-
tion guidelines, assisting their child, use of the electronic device, and their child’s 
pain experience. Results: The sample included 22 African American children (13 
females/9 males; 7= 4-5 year-olds, 12= 6-11 year-olds and 3= 12-17 year-olds). Pain 
was most commonly reported to occur in the legs, back, arms, stomach, or head. 
Those aged ≥ 7 years were able to demonstrate good understanding of the Modified 
FPS-R item and response scale and ability to use the electronic device. Children 4-6 
years were generally not familiar with “discomfort” and many did not know the 
meaning of “pain”. It was unclear whether these children were able to consider their 
worst pain over the course of the day and respond accordingly. Parents/legal guard-
ians noted that the instrument instructions were clear and that the administration 
guidelines provided simplified, standardized direction for young children and those 
unable to read without assistance. cOnclusiOns: The Modified FPS-R used with 
the administration guidelines where parental assistance is needed, is an appropri-
ate measure of sickle-cell pain over the course of a day for children aged ≥ 7 years.
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Objectives: To identify patient-reported outcomes (PROs) evaluating quality of 
life (QoL) in Gaucher Disease (GD) after formation of Rare-Diseases Program in 
2010 by the Center for Drug Evaluation and Research under United States Food 
and Drug Administration with a mission to acknowledge patient’s perceptions on 
treatment benefits. MethOds: Embase® and MEDLINE®databases were searched 
from January 2010 to May 2015. Studies published in English language were included 
irrespective of study designs by two independent reviewers with discrepancies rec-
onciled by a third independent reviewer. Results: Out of 325 studies retrieved from 
biomedical databases, only nine studies reporting seven different PRO instruments 
were included. Details of study conduct were adequately reported with no signifi-
cant difference between treatment groups. Six generic instruments were identified 
from the included studies, Short Form Health Survey with 36-items (SF-36; 5 studies), 
12-items (SF-12; 1 study), the European Quality of Life - Five Dimensions (EQ-5D; 
2 studies), Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F; 1 
study), Brief Pain Inventory (BPI; 1 study), and the Visual Analogue Scale (VAS; 1 
study). Only one study used the disease-specific Type 1 Gaucher Disease - Disease 
Severity Scoring System (GD-DS3) providing a reliable method of assessing both 
intra- and inter-patient severity indicating an impact of pain on the QoL. Overall, 
the results correlated with clinical outcomes in GD patients demonstrating poorer 
physical functioning than healthy controls. A review of HTA submissions showed 
that current evidence on QoL was not sufficient to assess disease impact with the 
French HTA agency (HAS) particularly encouraging the need to assess QoL to support 
evidence on treatment effects. cOnclusiOns: Variability in use of PRO instruments 
was seen among the included studies. Disease specific PRO measures are highly 
acceptable and need to be developed in orphan disease for better evaluation of QoL.
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individuAlS with chronic lower BAcK PAin in jAPAn
Montgomery W1, Vietri J2, Shi J3, Kariyasu S4, Ogawa K4
1Eli Lilly Australia, West Ryde, Australia, 2Kantar Health, Horsham, PA, USA, 3Kantar Health, 
Princeton, NJ, USA, 4Eli Lilly Japan K.K., Kobe, Japan
Objectives: To quantify the impact of pain severity on patient-reported out-
comes among individuals diagnosed with chronic lower back pain (CLBP) in 
Japan. MethOds: Data came from the 2012 Japan National Health and Wellness 
Survey (N= 29,997), a web-based survey of individuals in Japan aged ≥ 18 years. 
This analysis included respondents diagnosed with lower back pain of ≥ 3 months’ 
duration. Measures included the SF-36v2, Patient Health Questionnaire (PHQ-9), 
Generalized Anxiety Disorder 7-item (GAD-7) scale, Work Productivity and Activity 
Impairment questionnaire, and self-reported all-cause healthcare visits (6 months). 
Generalized linear models with appropriate link functions were used to assess the 
relationship between outcomes and severity of pain in the prior week as reported on 
a visual analog scale ranging from 0 (No pain) to 10 (Pain as bad as you can imagine) 
